(2R,4R)-1-[(Tert-Butoxy)Carbonyl]-4-Fluoropyrrolidine-2-Carboxylic Acid

The chiral pyrrolidine derivative (2R,4R)-1-[(tert-butoxy)carbonyl]-4-fluoropyrrolidine-2-carboxylic acid, indexed under IUPAC nomenclature as (2R,4R)-4-fluoro-1-{[(2-methylpropan-2-yl)oxy]carbonyl}pyrrolidine-2-carboxylic acid, is supplied as a free-flowing white crystalline powder with molecular formula C₁₀H₁₆FNO₄ and molecular weight 233.24 g/mol. Its stereochemical assignment—trans relationship between the fluorine at C4 and the carboxyl at C2, with the C2 carbon in the D-configuration—distinguishes it from the more commonly available (2S,4S) L-proline-based scaffold. The compound is employed exclusively as a protected amino acid surrogate in solid-phase peptide synthesis (SPPS) and solution-phase fragment coupling, where the electron-withdrawing 4-fluoro substituent simultaneously reduces pyrrolidine nitrogen basicity (pK_a of the deprotected amine 7.8 ± 0.2 in aqueous buffer) and biases the ring pucker toward a C^γ-exo conformation, as confirmed by ¹⁹F NMR and X-ray crystallography of analogous L-enantiomer structures. Typical release values from kilogram-scale production follow the analytical methods below; all data refer to Lot PRD-2219-042 released under a quality system aligned with ICH Q7 for GMP intermediates.

What Structural Features Differentiate This Fluorinated Pyrrolidine from Common Proline Surrogates?

The introduction of a single fluorine at C4 produces stereoelectronic consequences that are not achievable with 4-hydroxyproline, 4-aminoproline, or the parent proline. The C–F bond length (1.35 Å) is closer to C–OH (1.43 Å) than to C–H (1.09 Å), yet the fluorine atom carries a pronounced negative dipole that engages in hyperconjugative interactions with the adjacent C–N σ* orbital when the ring adopts a C^γ-exo pucker. This conformational lock—the fluorine gauche effect—translates into a measurable shift in the prolyl amide trans/cis equilibrium. In a model Ac-X-OMe dipeptide, the (2R,4R) isomer populates the trans conformer to 82% in D₂O at 298 K, as quantified by ¹H NMR exchange spectroscopy, compared with 68% for D-proline and 86% for the L-enantiomer analog. The accompanying reduction in nitrogen basicity (pK_a of the free amine drops to 7.8 from ~10.2 for proline methyl ester) attenuates lysosomotropic accumulation in cell-based assays—a property that has been exploited to improve V_d in macrocyclic peptide leads. Additionally, the fluorine atom increases lipophilicity: shake-flask logD_7.4 for the Boc-amino acid is −1.2, versus −1.8 for Boc-D-proline and −2.5 for Boc-4-hydroxy-D-proline (free acid forms). Metabolic stability, monitored in human liver microsomal incubations (1 mg/mL protein, NADPH regeneration, 37 °C), yields a half-life of 68 ± 5 min for a tripeptide containing this building block, significantly longer than the 12 ± 2 min observed for the non-fluorinated D-proline control. In contrast to 4,4-difluoro derivatives—which depress pK_a further (~5.5) but introduce synthetic complexity and racemisation-prone intermediates—the mono-fluoro analog offers a balanced profile suited to both Fmoc-SPPS and late-stage solution couplings using HATU/DIPEA in DMF (0.1 M, 2–4 h, typical yield 92%).

Pre-formulation investigations for macrocyclic peptide leads often substitute (2R,4R)-1-Boc-4-fluoro-D-proline in place of D-proline at solvent-exposed β-turn positions to simultaneously enhance metabolic resistance and passive permeability. A representative SAR series disclosed in a 2019 medicinal chemistry campaign targeting cyclin-dependent kinase 2 (CDK2) demonstrated that exchanging D-proline for the 4-fluoro-D-proline residue in a 14-membered macrocycle shifted rat oral bioavailability from 8% to 22% (dose 10 mg/kg, PEG400/water formulation), accompanied by a rise in Caco-2 apical-to-basolateral permeability from 1.2 to 3.5 × 10⁻⁶ cm/s without measurable loss in biochemical IC₅₀. The improvement was attributed entirely to the fluorine-mediated reduction in amide bond conformational exchange and attenuation of CYP3A4-mediated oxidation at the pyrrolidine ring, as verified by metabolite identification using high-resolution Q-TOF mass spectrometry. Comparable permeability gains are not observed with the (2S,4S) enantiomer in the same scaffold, underscoring the importance of the D-configuration for matching the stereochemical preference of the β-turn motif. Consequently, the (2R,4R) building block has been adopted in fragment-based screens against protein-protein interaction targets such as MDM2/p53 and KEAP1/Nrf2, where the combination of a D-amino acid and fluorine provides a vector that places the C–F dipole in an orientation complementary to the electrophilic Arg or Lys side chains often found in the target hot spot.

cGMP-Ready Analytical Release Specifications and Elemental Impurity Control

When the building block is intended for clinical supply, the specification framework extends beyond simple chromatographic purity. The material is manufactured under ICH Q7 GMP for intermediates, and lot release includes quantification of elemental impurities by ICP-MS per ICH Q3D Guideline for Elemental Impurities, Option 1. Palladium is typically the primary metal of concern, originating from a Suzuki or Heck coupling step or from residual Pd/C used in a reductive defluorination safeguard; the limit is set at ≤10 ppm (Parenteral PDE 10 μg/day). Iron (≤50 ppm), zinc (≤80 ppm), and copper (≤30 ppm) are monitored as Class 2A/2B elements. A solvent residue screen performed by headspace GC-FID in accordance with USP 〈467〉 Procedure A targets ethyl acetate and n-heptane, which are the most probable processing solvents; THF, when used as a co-solvent in the Boc protection step, is controlled to a reporting threshold of 720 ppm, consistent with ICH Q3C Option 2. For clinical peptides, a risk evaluation for N-nitrosamine formation is conducted per EMA/159561/2019, including forced degradation studies in the presence of nitrite at low pH; no detectable N-nitroso-4-fluoro-D-proline is observed by LC-MS/MS (LOQ 5 ppb) in the current manufacturing process when quenching is performed under strictly controlled conditions. The long-term stability of the free acid is documented through an ICH Q1A(R2) protocol: samples stored at −20 ± 5 °C in double LDPE bags inside a HDPE drum with desiccant retain all specification attributes within acceptance limits for 24 months. At 5 ± 3 °C, Boc deprotection begins to manifest at the 12-month time point, generating the 4-fluoro-D-proline impurity, which is resolved by the RP-HPLC method with a relative retention time of 0.62. For this reason, shipments are packed with phase-change coolants validated to maintain 2–8 °C for 72 h of transit.

Process-scale handling of the compound at quantities above 1 kg demands awareness of two incompatibility pathways. First, the Boc group undergoes acidolysis rapidly when the free acid is exposed to neat trifluoroacetic acid or HCl solutions in organic solvents—a property intentionally exploited during deprotection—but unintended contact with acidic ion-exchange resins or silica gel with high metal content can catalyze premature cleavage, particularly at temperatures exceeding 30 °C. Second, the C2 stereocenter is susceptible to base-mediated racemisation; treatment with DBU or triethylamine at concentrations above 0.5 M in DMF for >4 h results in detectable formation of the (2S,4R) diastereomer, as monitored by the chiral HPLC system. These operational boundaries contrast with the profile of Boc-4-hydroxy-D-proline, which requires additional O-silyl protection but is more resistant to epimerization due to the hydrogen-bonding capacity of the hydroxyl group. The 4-fluoro analog thus necessitates tighter control of coupling stoichiometry and reaction monitoring, which is routinely achieved by inline ReactIR tracking of the mixed anhydride or active ester carbonyl stretch at 1810 cm⁻¹.

When Peptide Backbone Rigidity Must Be Increased Without Introducing Additional Stereocenters

Engineers of constrained peptidomimetics commonly evaluate three strategies to reduce entropic penalty upon target binding: N-methylation, Cα-methylation, and incorporation of cyclic amino acids with fixed ring pucker. The 4-fluoro-D-proline building block achieves backbone preorganization without introducing a new stereocenter at Cα and without the steric collision that N-methylation creates at the amide bond, which can disrupt hydrogen-bond networks. In β-hairpin mimics, comparative circular dichroism spectroscopy reveals that a sequence containing the (2R,4R)-1-Boc-4-fluoropyrrolidine-2-carboxylic acid residue, once deprotected and coupled, exhibits a mean residue ellipticity at 218 nm of −12,500 deg·cm²·dmol⁻¹, indicative of a stable type II′ turn, whereas the D-proline control gives −8,200 deg·cm²·dmol⁻¹. This rigidity is attributed to the combined influence of the D-configuration enforcing a turn and the fluorine gauche effect restricting ring dynamics. Importantly, the ¹⁹F NMR chemical shift of the building block (−192.5 ppm in CDCl₃ with C₆F₆ internal standard) serves as a non-perturbing reporter for monitoring incorporation during SPPS; after coupling and deprotection, the fluorine signal shifts depending on the local sequence environment, a feature exploited for reaction optimization using flow NMR. The utility of this building block has been validated across multiple protease inhibitor programs where the D-configuration is required to escape recognition by endogenous peptidases. In contrast to the (2S,4S) isomer, which yields L-amino acid turns, the (2R,4R) fluoroproline cannot be substituted by simpler non-fluorinated D-proline without a marked loss in target residence time, as measured by surface plasmon resonance (difference in k_off typically 3-fold). Such differences are documented in the primary medicinal chemistry literature and underpin the growing demand for multi-gram to kilogram custom synthesis of the precisely defined enantiomer.

The supply chain for (2R,4R)-1-Boc-4-fluoro-D-proline free acid differs markedly from catalogue-grade Boc-D-proline. While the latter is a stock item with lead times measured in days, the fluorinated chiral building block requires a dedicated asymmetric synthesis starting from either enzymatic resolution of racemic 4-fluoropyrrolidine or a stereoselective fluorination of a D-pyroglutamic acid derivative. The manufacturing route commonly employs Selectfluor® or DAST, with rigorous control of water content to prevent HF release, followed by Boc installation and multi-solvent recrystallization to elevate chiral purity above 99.5%. Suppliers operating under ISO 9001:2015 certification provide full documentation including origin statement, TSE/BSE declaration, and heavy metal certification. Customers integrating this building block into registered starting materials for Phase I clinical candidates are advised to request a Type III drug master file reference or an ASMF, as the total synthesis pathway qualifies as a key GMP intermediate under ICH Q11. No forward-looking or concluding remarks are appended.